Voxzogo (vosoritide) — Medica

Initial criteria

• age < 18 years
• diagnosis of achondroplasia confirmed by genetic testing with identifiable mutation in FGFR3 gene
• epiphyses are open
• patient will not have limb-lengthening surgery during treatment with Voxzogo
• prescriber has confirmed patient is able to drink approximately 240 to 300 mL of fluid in the hour prior to Voxzogo administration
• medication is prescribed by or in consultation with a pediatric endocrinologist

Reauthorization criteria

• age < 18 years
• diagnosis of achondroplasia confirmed by genetic testing with identifiable mutation in FGFR3 gene
• epiphyses are open
• patient will not have limb-lengthening surgery during treatment with Voxzogo
• prescriber has confirmed patient is able to drink approximately 240 to 300 mL of fluid in the hour prior to Voxzogo administration
• medication is prescribed by or in consultation with a pediatric endocrinologist
• patient’s most recent annualized growth velocity continues to be above their baseline annualized growth velocity value (before treatment)

Approval duration

1 year